BeiGene appoints Changzhen Wu as head of manufacturing operations

He will be responsible for all aspects of construction of the Suzhou manufacturing facility, and will lead manufacturing operations for BeiGene’s small-molecules, including production, engineering, quality operations, supply chain and logistics.

“Changzhen is an extremely valuable addition to our team” said John V. Oyler, CEO of BeiGene. “He is very well respected and has many established relationships in the industry. His unparalleled knowledge in the production of small-molecule drugs, and overseeing plant construction to managing day to day operations, is a strong complement to our existing team and critical to our future strategies.”

Mr Wu brings over four decades of combined experience in engineering, manufacturing, operations, and process design and development. Prior to joining BeiGene, Mr Wu was at Pharmacia where he was instrumental in leading the construction of its oncology manufacturing plant in China. Previously, Mr Wu was the Head Plant Manager at Pfizer Pharmaceutical (WuXi) for over 10 years. Prior to Pfizer, he was the Chief Engineer at Sino-Sweden Pharmaceutical for 15 years. Mr Wu began his career at China North-West API Pharmaceutical, where he spent over 16 years as a process engineer. He graduated from Shanghai Medical University with a Bachelor’s degree in Pharmacology.

“I am thrilled to be joining BeiGene to help scale its operations to address both current needs, as well as future opportunities,” said Mr Wu. “We plan to not only grow our manufacturing operations, but also promote and work in conjunction with other divisions of BeiGene to achieve our company goals.”